12 results about "Adrenocortical hormone" patented technology

The present invention relates to a composition for maturation of adrenal organoids, a method for maturation of adrenal organoids using same, and a method for transplantation of organoids prepared by the method. In the present invention, the structurally and functionally mature adrenal organoids prepared under optimized culture conditions using the composition for maturation of adrenal organoids containing adrenocortical hormone and cyclic adenosine monophosphate have been structurally and functionally improved, and it was confirmed that the adrenal organoid chip having a three-dimensional vascular network structure manufactured using the same actually replaces the function of the adrenal gland without side effects after transplantation into a mouse. Accordingly, the present invention can be advantageously used for transplantation or regenerative therapy, drug screening, drug responsiveness evaluation, and the like.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and / or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment.Relacorilant may be orally administered for the treatment of pituitary tumors. Relacorilant may be orally administered to a fasted patient, or to a fed patient. Relacorilant may be administered in conjunction with other pituitary tumor targeting treatments, including surgical treatments, radiation treatments, chemotherapy for carcinomas, and other pharmaceutical treatments.

The present application relates to the technical field of inhalation anesthetic antagonism, and particularly relates to the application of a corticotropin-releasing hormone receptor antagonist in the preparation of an inhalation anesthetic antagonist. The present application first discovers that the corticotropin-releasing hormone receptor of the dorsal raphe nucleus is a key target of the action of an inhalation anesthetic, and that the oculomotor nerve parvocellular nucleus-dorsal raphe nucleus neural loop mediates the effect of an inhalation anesthetic, and that a corticotropin-releasing hormone receptor antagonist can block the excitatory effect of urocortin on the neurons of the dorsal raphe nucleus, thereby weakening the effect of an inhalation anesthetic. The present application first applies a corticotropin-releasing hormone receptor antagonist in the preparation of an inhalation anesthetic antagonist, fills the technical gap in this field, is conducive to the rapid postoperative recovery of patients under general anesthesia, and has a broad application prospect.

Provided is a modified Urocortin 3 (Ucn3) comprising a covalently attached polymer comprising amino acids, wherein the polymer inhibits degradation and / or elimination of the modified Ucn3 in a subject, and wherein the modified Ucn3 retains corticotropin-releasing factor receptor type 2 (CRFR2) agonist activity. Also provided is a nucleic acid molecule encoding the modified Ucn3. Additionally provided is a vector comprising the above-described nucleic acid molecule. Further provided is a cell comprising the above-described vector. A method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by CRFR2 activity is also provided. A method of preparing the above-described modified Ucn3 is additionally provided. Further provided is a method of preparing the above-described modified Ucn3. Use of the above-described modified Ucn3, the above-described nucleic acid, the above-described vector, and the above-described cell for the manufacture of a medicament for the treatment of a disease, disorder, or medical condition mediated by CRFR2 activity is also provided.

Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and / or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment.Relacorilant may be orally administered for the treatment of pituitary tumors. Relacorilant may be orally administered to a fasted patient, or to a fed patient. Relacorilant may be administered in conjunction with other pituitary tumor targeting treatments, including surgical treatments, radiation treatments, chemotherapy for carcinomas, and other pharmaceutical treatments.

The invention discloses application of rubber tree seed oil in preparation of a product for improving or treating kidney-yang deficiency, and belongs to the technical field of medicines. The hevea brasiliensis seed oil can improve the levels of serum adrenocorticotropin releasing hormone, adrenocorticotropin and corticosterone by adjusting the hypothalamus-pituitary-adrenal axis function so as to improve the related signs of kidney-yang deficiency, such as intolerance of cold and liking warm, cold limbs, lassitude, reduced autonomous activity and the like. The invention further discloses a composition containing the hevea brasiliensis seed oil. The composition can be prepared into medicines, health-care foods or functional foods. The invention provides a new choice which is single in component, clear in mechanism, safe and effective for the treatment of kidney-yang deficiency.

Provided are a corticotropin releasing factor 2 receptor agonist and use thereof. The corticotropin releasing factor 2 receptor agonist can be used for preventing and / or treating heart failure, hypertension, obesity, sarcopenia, diabetes, chronic kidney disease, and related diseases.

The present disclosure provides a method of reducing formation of one or more adhesions in a patient by administering a CRH1 receptor antagonist to the patient. Additional methods of administering a CRH1 receptor antagonist to patients are also provided, including methods of reducing gastrointestinal damage, reducing inflammation, and reducing pain.

The invention discloses a probiotic medicinal and edible medicinal material composition as well as a preparation method and application thereof. The composition comprises combined probiotics and medicinal and edible medicinal materials, the combined probiotics comprise Lactobacillus plantarum JY001 and Lactobacillus plantarum JY002, and the medicinal and edible medicinal materials comprise cistanche deserticola, semen raphani, peach kernels, astragalus membranaceus, codonopsis pilosula and pericarpium citri reticulatae. The composition takes medicinal and edible medicinal materials as raw materials, has the effect of improving endocrine hormone disorder caused by chronic stress after being fermented by combined probiotics, and can be applied to preparation of products for improving endocrine hormone disorder caused by chronic stress; the composition is especially applied to preparation of products for reversing reduction of thyroid stimulating hormone release hormone, adrenocorticotropic hormone and / or testosterone secretion level caused by chronic stress, and meanwhile, the composition also meets the requirements of people for resisting fatigue and improving constipation due to intestinal dryness.

Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2α, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules. This resulted in the identification of negative allosteric modulators (NAMs) of the CRFBP(10 kD)-CRF2 complex that blunt CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission in dopamine neurons in the ventral tegmental area (VTA). These results provide the first evidence of specific roles for CRF2 and CRFBP in the modulation of neuronal activity and suggest that NMDARs in the VTA may be a target for the treatment of stress and substance abuse disorders such as alcohol use disorder.